Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | NPC1 | O15118 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28274627 | 0.78 | RAB9A (0.57) | RAB9ANPC1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL19332321 | 0.77 | RAB9A (0.75) | RAB9ANPC1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL2732151 | 0.75 | ALDH1A1 (0.44) | KMT2AALDH1A1HDAC1PDE4D | |
| SCHEMBL16416886 | 0.75 | NPC1 (0.60) | RAB9ANPC1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL12881525 | 0.73 | RAB9A (0.56) | RAB9ANPC1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL15205297 | 0.73 | ALDH1A1 (0.43) | KMT2AALDH1A1HDAC1PDE4D | |
| SCHEMBL12852349 | 0.72 | ATM (0.53) | RAB9ANPC1KMT2AHDAC1HDAC6 | |
| SCHEMBL1126857 | 0.72 | KMT2A (0.64) | RAB9ANPC1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL1877283 | 0.72 | RAB9A (0.57) | RAB9ANPC1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL23808915 | 0.71 | KMT2A (0.63) | RAB9ANPC1KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2019-05-21 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2017-10-26 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| US-9737534-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-22 | — | — | US | disclosed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | disclosed |
| EP-3067347-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2016-09-14 | — | — | EP | disclosed |
| EP-2632906-B1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LTD (IN) | 2016-04-06 | — | — | EP | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-01-28 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| US-9169242-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | LUPIN LIMITED (IN) | 2015-10-27 | — | — | US | disclosed |
| EP-2632906-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | Lupin Limited (IN) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-08-29 | — | — | US | disclosed |
| WO-2012056478-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | LUPIN LIMITED (IN) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022673-A1 | OXAZOLE AND ISOXAZOLE CRAC MODULATORS | RYR2, RYR1, GABRR1 | RAB9A 3236/4885NPC1 1168/4885KMT2A 4461/4885 |
| US-10292981-B2 | Oxazoline and isoxazoline derivatives as CRAC modulators | RYR2, RYR1, ADRA2C | RAB9A 3213/4885NPC1 1260/4885KMT2A 4046/4885 |
| US-20170304299-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | RAB9A 3278/4885NPC1 1274/4885KMT2A 3991/4885 |
| US-20130225600-A1 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | RYR2, ADRA2C, RYR1 | RAB9A 3278/4885NPC1 1274/4885KMT2A 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.